17 Years After Viagra, the Female Viagra May Finally Be Here

Flibanserin, a drug to treat low sexual desire in women.Allen Breed/AP


A contentious effort to introduce a sex-drive drug for women may be nearing a climax. After rejecting “the pink Viagra” (AKA flibanserin) twice in the past five years, a Federal Drug Administration advisory committee voted today that the the pill should be approved if measures are taken to reduce its potential side effects, such as low blood pressure and fainting.

The nonhormonal drug, developed by Sprout Pharmaceutical, is meant to be taken nightly. The company says it works by altering chemicals in the brain to increase a woman’s sexual desire (unlike Viagra, which increases blood flow to certain parts of the body). Women who took the drug in trials reported no more than one additional “sexually satisfying event” per month than women who received a placebo.

Women who took the drug in trials reported no more than one additional “sexually satisfying event” per month than women who received a placebo.

Today’s vote comes 17 years after the FDA approved Viagra, the incredibly profitable erectile dysfunction treatment. Since then, more than two dozen prescription drugs have been approved to assist with male sexual performance, but none for women.

Even the Score, a group backed by the pharmaceutical companies that developed flibanserin, says that women also suffer from sexual dysfunction and that the unwillingness to develop and approve drugs to treat it is a matter of bias. They called today’s vote a victory for gender equality. “Women with Hypoactive Sexual Desire Disorder deserve the safety and peace of mind that comes with access to FDA-approved medical treatment options, and today we write a new chapter in the fight for equity in sexual health,” Even the Score said in a statement.

But others believe that potentially profitable drugs for a dubious disorder are being pushed with little proven effectiveness. “I don’t think there is anything sexist about denying approval for drugs that don’t have an adequate risk-to-benefit ratio,” Thea Cacchioni, a professor of women’s studies at the University of Victoria in British Columbia, told the New York Times. According to Forbes, $50 million in private investment rest on flibanserin’s approval.

The FDA is expected to come to a final decision on the drug in August.

OUR NEW CORRUPTION PROJECT

The more we thought about how MoJo's journalism can have the most impact heading into the 2020 election, the more we realized that so many of today's stories come down to corruption: democracy and the rule of law being undermined by the wealthy and powerful for their own gain.

So we're launching a new Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption. We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We'll publish what we find as a major series in the summer of 2020, including a special issue of our magazine, a dedicated online portal, and video and podcast series so it doesn't get lost in the daily deluge of breaking news.

It's unlike anything we've done before and we've got seed funding to get started, but we're asking readers to help crowdfund this new beat with an additional $500,000 so we can go even bigger. You can read why we're taking this approach and what we want to accomplish in "Corruption Isn't Just Another Scandal. It's the Rot Beneath All of Them," and if you like how it sounds, please help fund it with a tax-deductible donation today.

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate